18F-FDG PET for Posttreatment Assessment of HD and NHL
| Assessment | Recommendation (according to Juweid et al. (23)) |
|---|---|
| HD: at completion of therapy | Perform biopsy on PET-positive lesions before salvage therapy; expect an 11% rate of unnecessary biopsies |
| PET-negative patients do not need biopsy, even with a large residual mass | |
| NHL: at completion of therapy (patients with diffuse large B-cell lymphoma) | Perform biopsy on PET-positive lesions before salvage therapy; expect a 7.5% rate of unnecessary biopsies |
| PET-negative patients do not need biopsy |